Pancreatic Cancer Research

ResearcherUniversity of BernActive in the last 2 years

Aurel A. Perren

Matched on ORCID iD 0000-0002-6819-6092; OpenAlex author ID A5046167689, A5104911209. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
17
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. RNF43 Mutations Are Associated With the Classical Molecular Subtype, Vigorous Antitumor Immune Responses, and Prolonged Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.modpat.2026.101010↗
  2. Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heteroge… Co-author DOI 10.1038/s41416-025-02959-w↗
  3. Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-24-0368↗
  4. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-329371↗
  5. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity. Last author DOI 10.1016/j.ejca.2022.03.033↗
  6. PD-1/PD-L1-Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups. Last author DOI 10.1158/2326-6066.cir-21-0144↗
  7. Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imagin… Co-author DOI 10.1002/prca.201800046↗
  8. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. Co-author DOI 10.1158/1078-0432.ccr-17-3401↗
  9. PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential. Co-author DOI 10.1016/j.ejca.2016.06.013↗
  10. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal … Co-author DOI 10.1038/bjc.2015.177↗
  11. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an inde… Co-author DOI 10.18632/oncotarget.2775↗
  12. Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic du… Last author DOI 10.1186/1479-5876-11-311↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Beat Gloor · 11 shared papers, 2013–2026 · strength 1.69
  2. Eva Karamitopoulou · 11 shared papers, 2013–2026 · strength 1.69
  3. Anna Silvia Wenning · 4 shared papers, 2022–2026 · strength 0.97
  4. Pauline Aeschbacher · 3 shared papers, 2023–2026 · strength 0.77
  5. Animesh Acharjee · 3 shared papers, 2023–2026 · strength 0.77
  6. Martin Wartenberg · 5 shared papers, 2015–2025 · strength 0.52
  7. Alessandro Lugli · 5 shared papers, 2013–2025 · strength 0.49
  8. José A. Galván · 3 shared papers, 2015–2025 · strength 0.39
  9. Andréas Andreou · 2 shared papers, 2021–2022 · strength 0.36
  10. Konstantin Bräutigam · 1 shared paper, 2026 · strength 0.33
  11. Erik Vassella · 2 shared papers, 2016–2018 · strength 0.13
  12. Jörg Kriegsmann · 1 shared paper, 2019 · strength 0.10
  13. Rita Casadonte · 1 shared paper, 2019 · strength 0.10
  14. Thilo Welsch · 1 shared paper, 2019 · strength 0.10
  15. Christian P. Pilarsky · 1 shared paper, 2019 · strength 0.10
  16. Mathias Worni · 1 shared paper, 2018 · strength 0.08
  17. Agathi I. Kondi-Pafiti · 1 shared paper, 2013 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.